Conclusions
metabolic syndrome, MetS, T2DM, atherosclerotic disease
METABOLIC SYNDROME, INSULIN RESISTANCE, TYPE 2 DIABETES MELLITUS
Chiglitazar shows promising efficacy for glycemic control in patients with T2DM associated with MetS or IR. Further prospective trials are required to validate these findings.
Risk for atherosclerotic disease increases when type 2 diabetes mellitus (T2DM) is associated with metabolic syndrome (MetS).T2DM patients who present with MetS or insulin resistance show better improvement with the chiglitazar treatment. These results indicate a preferable population for chiglitazar treatment.
